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ABSTRACT 
Objective: To identify studies describing the prevalence of xerostomia in breast cancer patients undergoing 
chemotherapy. Method: Integrative review based on the guiding question << What is the scientific evidence 
on the prevalence of xerostomia in breast cancer patients undergoing chemotherapy? >>. We searched the US 
National Library of Medicine and National Institute of Health, Latin American and Caribbean Health Sciences 
Literature and Scientific Electronic Library Online databases using the Health Sciences Descriptors. We found 
63 articles, which were analyzed by two researchers, following the inclusion and exclusion criteria. Results: 
The prevalence of xerostomia was described in 10 articles that used scales, questionnaires with dichotomous 
answers, and sialometry as evaluation method. Conclusion: A prevalence of 47% to 77.3% of xerostomia 
during chemotherapy was identified.
Descriptors: Xerostomia; Breast neoplasms; Adjuvant chemotherapy; Antineoplastic agents; Drug therapy.
RESUMO 
Objetivo: Identificar os estudos que descrevem a prevalência de xerostomia em pacientes com câncer de mama e em quimioterapia. 
Método: Revisão integrativa, partindo da questão norteadora << Quais as evidências científicas sobre a prevalência de xerostomia em 
pacientes com câncer de mama e em quimioterapia? >>. Foi realizada uma busca nas bases de dados: US National Library of Medicine 
and National Institute of Health, Literatura Latino-Americana e do Caribe em Ciências da Saúde e Scientific Electronic Library Online por 
meio dos Descritores em Ciências da Saúde. Foram encontrados 63 artigos, analisados por dois pesquisadores seguindo os critérios de 
inclusão e exclusão. Resultados: A prevalência de xerostomia foi descrita em 10 artigos que utilizaram como método de avaliação escalas, 
questionários com respostas dicotômicas e sialometria. Conclusão: Identificou-se uma prevalência de 47% a 77,3% de xerostomia durante 
a quimioterapia. 
Descritores: Xerostomia; Neoplasias da mama; Quimioterapia adjuvante; Antineoplásicos; Tratamento farmacológico.
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RESUMEN
Objetivo: Identificar estudios que describan la prevalencia de xerostomía 
en pacientes con cáncer de mama y quimioterapia. Método: Revisión 
integradora, basada en la pregunta guía << ¿Cuál es la evidencia 
científica sobre la prevalencia de xerostomía en pacientes con cáncer 
de mama y quimioterapia? >>. Se realizaron búsquedas en las bases de 
datos US National Library of Medicine and National Institute of Health, 
Literatura Latino-Americana y del Caribe en Ciencias de la Salud 
y Scientific Electronic Library Online utilizando los Descriptores de 
Ciencias de la Salud. Encontramos 63 artículos, que fueron analizados 
por dos investigadores siguiendo los criterios de inclusión y exclusión. 
Resultados: La prevalencia de xerostomía se describió en 10 artículos que 
utilizaron escalas, cuestionarios con respuestas dicotómicas y sialometría 
como método de evaluación. Conclusión: Se identificó una prevalencia de 
xerostomía del 47% al 77,3% durante la quimioterapia.
Descriptores: Xerostomía; Neoplasias de la mama; Quimioterapia 
adyuvante; Antineoplásicos; Quimioterapia.
INTRODUCTION
Breast cancer is a growing problem worldwide and there 
are many policies for its early detection and diagnosis. It is 
recommended that the beginning of treatment occurs within 
60 days, according to Law No. 12,732 of November 22, 2012.1
In 2018 and 2019, 59,700 new cases of breast cancer are 
expected, with an increase of approximately 1,740 cases 
(2.9%) as estimated in 2016 by the National Cancer Institute 
(INCA) .1-2
Among the non-surgical treatments used for breast 
cancer, we can highlight chemotherapy. One of the side effects 
related to this therapy is xerostomia, defined as a subjective 
sensation of dry mouth, usually associated with decreased 
salivary flow.3-5
The emergence of xerostomia during chemotherapy 
occurs because mucosal cells suffer the effects of drugs 
that act on the destruction or inhibition of cell growth, not 
differentiating neoplastic cells from normal ones.5
Xerostomia can also lead to conditions such as burning 
mouth that compromises chewing and swallowing, bringing 
consequences to health in general and compromising the 
quality of life.4,6
For its evaluation, some studies use salivary flow 
measurement, but a study conducted in 2017 showed 
that hyposalivation, a complaint usually associated with 
xerostomia, is not always true since most patients with dry 
mouth sensation had normal salivary flow. (70%)7
Another means of assessing xerostomia is the Thomson 
questionnaire created in 1999, known as the “Xerostomia 
Inventory”, consisting of 11 items designed to assess various 
dry mouth sensation situations, with five response options 
ranging from one to five.4
In this context, the objective of this review was to identify 
in the literature studies that describe the prevalence of 
xerostomia in breast cancer and chemotherapy patients, 
contributing to a reflection of this problem in this population.
METHOD
This is an integrative review carried out in six stages: 
the first with the definition of the guiding question and the 
research objective; the second with the selection and crossings 
of the descriptors and searching the databases; the third 
included the description of the inclusion and exclusion criteria 
of the articles found; the fourth was the analysis of articles 
by two researchers following the inclusion and exclusion 
criteria and content evaluation; the fifth with the discussion 
of the selected articles and the sixth and last stage, with the 
conclusion of the research itself.
The guiding question “What is the scientific evidence 
on the prevalence of xerostomia in breast cancer and 
chemotherapy patients?” Was elaborated in view of the PICO 
strategy: participants, intervention, control or comparison 
and outcome.8 This question led us to Objective: To identify 
studies describing the prevalence of xerostomia in patients 
with breast cancer and chemotherapy.
The selection of descriptors and databases for the search 
as well as the crossings were performed by the researchers 
together with a professional librarian in order to find all 
articles that corresponded to the theme.
The articles were searched in the scientific databases: US 
National Library of Medicine and National Institute of Health 
(PubMed), Latin American and Caribbean Health Sciences 
Literature (LILACS) and Scientific Electronic Library Online 
(SciELO) in the period. from March 4 to May 3, 2019, with 
the Descriptors in Health Sciences (DeCS).
The inclusion criteria of the articles were: scientific 
articles in the languages: Portuguese, Spanish and English 
and without time limit. Theses, dissertations, monographs, 
letters and health information were excluded. After reading 
the abstracts, those that did not correspond to the study 
theme and those that were duplicated in the databases were 
also excluded.
The scientific articles were analyzed by two independent 
researchers who considered the inclusion and exclusion 
criteria, the level of evidence9 of the studies and the content, 
seeking to answer the review question.
A data extraction instrument was created and 
standardized for this review and the results were later 
entered into the database and double-checked. Research 
type, sample size, main results, and study completion were 
the main documented characteristics for presentation of 
results and discussion.
All differences were discussed between the researchers 
and in case of disagreement an external evaluator was invited 
to give their opinion.
RESULTS
The data presented in Table 1 show the search performed 
in the three scientific databases.
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(breast neoplasms OR breast 
cancer) AND (Chemotherap* OR 
drug therapy OR Antineoplastic 
Agents OR Antineoplast* OR 
Pharmacotherap*) AND (Xerostomia 




Neoplasias da Mama OR 
(neoplas$ AND mama$) OR 
(cancer AND mama$) OR Câncer 
da Mama OR breast neoplasms 
OR (breast AND neoplas$) OR 
breast cancer OR (breast AND 
cancer) [Palavras] and Xerostomia 
OR Asialia$ OR assialia$ OR 
Hyposalivation$ OR Hiposalivação 
OR Mouth Dryness OR (Secura AND 
Boca) [Palavras]
08
SciELO (mama) AND (xerostomia) 02
Total 63
After reading the titles and abstracts, 49 were excluded that 
did not correspond to the theme studied and four by duplicity. 
Thus, this integrative review analyzed 10 scientific articles.
The studies included in this review were classified 
according to the level of evidence, being five (50%) 3A and 
five (50%) 3B. There were a higher number of publications in 
2017 and 2018 and, in relation to the location of the research, 
four (40%) were made in Brazil.
Samples from seven (70%) studies were from female 
populations diagnosed with breast cancer and three (30%) 
from both sexes including cancers other than breast cancer.
Regarding the method performed for the evaluation of 
xerostomia, four (40%) studies used measuring instruments 
such as: Likert scale; Symptom Assessment System 
(ESAS), modified Norwegian version; Udvalg for Kliniske 
Undersoegelser (UKU) is an instrument proposed by Philip 
Fox in 1987.
Questionnaires with dichotomous answers (present or 
absent / yes or no) were applied in four (40%) studies. One 
study performed sialometry and another did not describe 
the method used.
The timing of the application of xerostomia evaluation tests 
varied between the initiation of chemotherapy by one (10%) 
study, chemotherapy in four studies (40%), chemotherapy 
in two studies (20%) and all times in three studies (30%).
The prevalence of xerostomia in the studies was from 0% 
to 20.2% before chemotherapy, from 47% to 77.3% during 
and from 30% to 56.3% after treatment.
Table 2 presents the main results of the articles selected 
in this review.




In the last 12 months 85 women (56.3%) reported xerostomia. In the multivariate analysis, women with 
xerostomia and more than three restored teeth had, respectively, 2.92 times (95% Confidence Interval (CI) 1.20 
to 7.09) and 1.98 times (95% CI 1.01 to 3.87) greater chance of having a negative impact on oral health-related 
quality of life when compared to women without xerostomia and those with fewer restorations.
Taichman 
LS et al.11 
When comparing three groups of breast cancer patients to salivary flow, the aromatase inhibitor group 
was significantly more affected with xerostomia than the tamoxifen and chemotherapy groups. And when 
compared to breast cancer patients with those without diagnosis, xerostomia was 2.48 times more prevalent 
in the group with the disease (2.48 versus 1.70; p <0.01).
Marinho 
EDC et al.12 




Xerostomia was not reported by any patient prior to the start of chemotherapy. This symptom became 
present as chemotherapy began, with 34 patients (65.4%) reporting xerostomia during the first follow-up and 
23 patients (44.2%) in the second. Xerostomia and other oral disorders increased from 28.8% to 50% during 
chemotherapy.
Sözeri E et 
al.14 
Xerostomia was reported in 109 patients (59.2%). The average scores of patients with xerostomia, obtained 
from the subscales of “Decline of basic taste” and “Fantogeusia and Parageusia”, were higher than those who 
did not report xerostomia.
Lancheros 
L et al.15 
Xerostomia was present in 15 of 25 women (60%) in the first cycle, 13 (52%) in the second cycle and 15.3 
(61.3%) in the third cycle of chemotherapy.
Wilberg P 
et al.16 
In this study 91 patients (59%) reported xerostomia at the time of physical examination.
Jensen SB 
et al.17 
Through the UKU scale xerostomia was present in 48 of 75 women (64%) during chemotherapy, 28.5 (38%) 
after six months and 29.2 (39%) after one year. By Fox's instrument xerostomia was reported at 1.5 (2%) before 
chemotherapy, 35.2 (47%) during and 22.5 (30%) after one year. The prevalence of xerostomia remained 
significantly higher at one year after chemotherapy compared with the daily sensation of dry mouth, although 
the stimulated salivary flow rates had not normalized.
Araujo TLC 
et al.18 
In this study 56.4 patients (77.3%) were diagnosed with xerostomia. The results showed that xerostomia was 
the most common oral pathological condition among patients undergoing chemotherapy.
Musso MAA 
et al.19
Xerostomia was present in 18 of 89 women (20.2%). There was a statistically significant difference when 
associated with xerostomia with age and race / color. Women 60 years of age and older (odds ratio (OR) = 
3,460) and white women (OR = 3,452) were about three times more likely to have xerostomia.
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DISCUSSION
We observed a limited number of publications on the 
theme: breast cancer and xerostomia. This fact made it 
difficult to identify the prevalence of xerostomia in both 
the general population and in patients with breast cancer 
and chemotherapy.
A systematic review conducted in 2018 showed an 
estimated overall prevalence of 22.0% xerostomia.4
In Brazil, where most of the studies in this review were 
performed, the prevalence of xerostomia in the general 
population was demonstrated in an ecological study, 
descriptive of correlation with secondary data analysis, 
performed in the city of Piracicaba in 2012 was 17%. 20
We can observe from these data that even in countries 
with a higher prevalence than described in Brazil, there are 
few studies involving this problem.4
Xerostomia evaluation methods have not been clearly 
presented in some studies. Those who used specific scales, 
questionnaires or instruments for the evaluation of xerostomia 
somehow standardized the approach in their sample and tried 
to evaluate a subjective complaint according to dry mouth 
situations and intensity, unlike studies that only identified 
the presence or absence of this sensation.
Measurement of salivary flow or sialometry is a method 
that enables the identification of the decrease in salivary 
flow that may or may not be associated with xerostomia, 
as demonstrated in a study conducted in Chile in 2017, 
where 556 patients were diagnosed with xerostomia using a 
questionnaire. performed sialometry with and without salivary 
stimulation, finding that hyposalivation was present in almost 
30% of patients who complained of xerostomia.11
As we can see, there is no specific method for the 
identification of xerostomia, since this sensation is subjective, 
but one should look for the most appropriate method for 
the studied population, as well as the appropriate time for 
its application.
The fact that some studies evaluated patients before 
chemotherapy allowed the identification of previous 
xerostomia and allowed the observation of an increase 
or decrease of this complaint during and after the end 
of treatment.
CONCLUSION
A discrepancy in values regarding the prevalence of 
xerostomia in breast cancer patients and chemotherapy was 
identified. This fact may be associated with the population 
profile, age, ethnicity, associated diseases, medication use, 
among other factors.
The findings of this review contribute to the development 
of new studies focused on this problem and to the elaboration 
of actions that minimize this discomfort and improve the 
patients’ quality of life.
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